Jeff Wolf, CEO, Heat Biologics describes the vaccine platform Heat has developed originally for oncology and their licensing agreement with the University of Miami to use the same vaccine approach for NIH-funded studies against Zika, malaria, and HIV against the Coronavirus. Their novel approach is using allogeneic off-the-shelf contained cell based therapy that delivers a potent cell protein called GP96 that secretes antigens to activate T cells to attack the virus.
#Coronavirus #COVID19
HeatBio.com
Download the transcript here
Empowered Patient Podcast